Amgen (MEX:AMG N) 3-Year Share Buyback Ratio : 1.30% (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Amgen 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Amgen's current 3-Year Share Buyback Ratio was 1.30%.

The historical rank and industry rank for Amgen's 3-Year Share Buyback Ratio or its related term are showing as below:

MEX:AMG N' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1 Med: 1.6 Max: 8.7
Current: 1.3

During the past 13 years, Amgen's highest 3-Year Share Buyback Ratio was 8.70%. The lowest was -10.10%. And the median was 1.60%.

MEX:AMG N's 3-Year Share Buyback Ratio is ranked better than
93.78% of 675 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs MEX:AMG N: 1.30

Competitive Comparison of Amgen's 3-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Amgen's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Amgen 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Amgen (MEX:AMG N) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Amgen 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Amgen's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (MEX:AMG N) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

AMGN:USA 1AMGN:Italy AMGd:UK 0R0T:UK AMG:Germany AMGN:Canada AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines